Clinical Trial Update: A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety of weekly subcutaneous pegzilarginase in arginase 1 deficiency has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arginase Deficiency
• Hyperargininemia

Drugs mentioned

• Pegzilarginase (pegzilarginase)

Snippet

Sponsor: Aeglea Biotherapeutics | Conditions: Arginase I Deficiency, Hyperargininemia | Phase 3 | Status: TERMINATED